Bioventus Inc. Acquires Misonix, Inc.
July 29, 2021
Bioventus Inc. entered into a definitive agreement to acquire Misonix, Inc. in a cash-and-stock transaction that values Misonix at approximately $518 million on a fully diluted basis. The deal expands Bioventus' regenerative medicine and surgical solutions portfolio by adding Misonix's minimally invasive ultrasonic technologies and regenerative wound products and is expected to close in the fourth quarter of 2021 subject to customary approvals.
- Buyers
- Bioventus Inc.
- Targets
- Misonix, Inc.
- Sellers
- Misonix stockholders (including Stavros Vizirgianakis, SV Health Investors, 1315 Capital)
- Industry
- Medical Devices
- Location
- New York, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.